Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) in The Red for The Week

The main US indices ended Friday’s session weaker, as US economic growth cooled to the slowest pace in three years in the first quarter and geopolitical concerns reemerged.

Cytokinetics, Incorporated (NASDAQ:CYTK) stock has moved in a downward direction this week, causing concern for some investors.  Based on the recent close, the shares have dropped -1.01% over the past five trading days.  Looking slightly further out, the stock is 20.99% year to date.  With increased market volatility, stakeholders will likely be deciding whether or not now is a good time to cut losses or double down on the pullback.

Analyst Recommendation
Wall Street analysts are still seeing some upside to Cytokinetics, Incorporated (NASDAQ:CYTK) despite the recent move. Sell-side firms, on a consensus basis have a $21.86 price target on the name and a 1.90 recommendation, according to First Call. The recommendation is based on a 1 to 5 scale where 1 or 2 indicates a Buy recommendation, 3 a Hold and 4-5 a Sell.

In taking a look at technical levels,Cytokinetics, Incorporated (NASDAQ:CYTK) shares are trading 9.80% away from the 50 day simple moving average and 14.81% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -14.53% away from it’s 52- week high and 72.74% away from its 52 week low.

After the recent decrease, investors may also look to see if the stock has entered oversold territory and could possibly ripe for a reversal.

Traditionally a stock is considered to be oversold when the Relative Strength Index moves below 30 As of writing, Cytokinetics, Incorporated’s RSI stands at 63.86 .

In looking at volatility levels, the shares saw weekly volatility of 4.81% and 4.30% over the past month.

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts.  This is not a recommendation to buy or sell Cytokinetics, Incorporated (NASDAQ:CYTK).

Leave A Reply

Your email address will not be published.